GIP
5 articles
PharmacologyACS Pharmacology & Translational Science
Review: Adding Exercise to Incretin Drugs Remains Unproven in Obesity
- A systematic review of 31 studies pooled roughly 10,000 adults with excess weight and compared incretin drugs, exercise, and the two together.
- Drugs reliably beat placebo or usual care on weight and glycaemia, but few trials tested drug plus exercise head-to-head against drug alone.
- Exercise regimens varied widely, often amounting to counselling, so any complementary benefit for fitness or weight maintenance is only tentative.
Thirty-one studies and almost no head-to-head drug+exercise versus drug-alone arms: the question clinicians actually ask is barely tested. The pharmacologically interesting endpoint is lean-mass preservation during incretin weight loss, which needs DXA or MRI body composition, not scale weight. Until trials use standardized, supervised training with body-composition and fitness readouts, 'add exercise' stays a plausible hypothesis, not evidence.
Computational & AIJournal of Chemical Information and Modeling (ACS)
Consensus ligand- and structure-based virtual screening uncovers chemically diverse GLP-1 receptor agonists, including a small peptide with dual GIPR activity
- The pipeline combines ligand-based descriptors, multi-fingerprint and electrostatic similarity, pharmacophore models and docking to several receptor conformations, with a consensus rule to pick compounds.
- It targets the flexible class B1 GLP-1 receptor, where single-method screens tend to be biased and recover few chemotypes.
- Selected hits were tested in cells, then probed by binding-site mutagenesis and competition binding.
- Three structurally distinct agonists emerged, one non-peptide and two peptides; a pentapeptide acted as a full agonist, also hit GIPR, but with modest potency.
Three hits is a result, but the missing number is hit rate against how many compounds were tested, and against a plain docking-only or similarity-only baseline. Without that, consensus value is unproven. For a team: check whether the pentapeptide's activity is real receptor pharmacology, and whether modest potency leaves room for optimisation.
Industry NewsEli Lilly / Novo NordiskBioPharma Dive
Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes
- Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
- Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
- The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
A head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.
Industry NewsNovo Nordisk / Jiangsu Hengrui PharmaceuticalsEndpoints News
Novo Pays $300M Upfront for Hengrui's Weekly Oral GLP-1/GIP Agonist
- Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties.
- The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.
Paying $300M upfront for a molecule that hasn't dosed a human outside China shows how badly Novo wants an oral follow-on while Lilly presses its lead. It also fits a pattern of buying de-risked-enough optionality from outside rather than building it, after smaller deals like Nanexa. Weekly oral bioavailability is the real technical risk, and the milestone-heavy structure shields Novo if it fails.
Industry NewsRocheFierce Biotech
Roche's Enicepatide Hits Phase II Goals in Diabetes and Obesity Trial
- Enicepatide (CT-388), Roche's dual GLP-1/GIP receptor agonist, met both primary endpoints in a Phase II trial in type 2 diabetes with overweight or obesity.
- At 48 weeks, the top 24 mg dose drove dose-dependent weight loss near 15% with no plateau, plus strong glycemic improvement.
- Most high-dose patients reached near-normal HbA1c, and Roche is now advancing Phase III programs (ENITH-1, ENITH-2) plus a glycemic-control study.
Roche just cashed in its $2.7B Carmot acquisition: a 15% weight-loss curve still climbing at 48 weeks puts enicepatide in contention with Lilly's retatrutide and Novo's CagriSema, not just chasing tirzepatide. More importantly, it hands Roche a credible re-entry into metabolic disease after sitting out the incretin boom — Phase III now becomes the real test of manufacturing and commercial scale-up against entrenched leaders.